Showing 2,141 - 2,160 results of 3,102 for search '".gov"', query time: 0.09s Refine Results
  1. 2141

    Strategies to Enhance Nanocrystal Formulations for Overcoming Physiological Barriers Across Diverse Routes of Administration by Yanamadala Y, Muthumula CMR, Khare S, Gokulan K

    Published 2025-01-01
    “…Yaswanthi Yanamadala,* Chandra Mohan Reddy Muthumula,* Sangeeta Khare, Kuppan Gokulan Division of Microbiology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, 72079, USA*These authors contributed equally to this workCorrespondence: Kuppan Gokulan, Division of Microbiology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, 72079, USA, Email Kuppan.gokulan@fda.hhs.govAbstract: Poor aqueous solubility and bioavailability limit the translation of new drug candidates into clinical applications. …”
    Get full text
    Article
  2. 2142

    Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinica... by Muhammad Candragupta Jihwaprani, Yipeng Sun, Wahyu Choirur Rizky, Idris Sula, Nazmus Saquib

    Published 2024-01-01
    “…In this systematic review and meta-analysis, five databases (i.e., ClinicalTrials.gov, Cochrane CENTRAL, PubMed, ScienceDirect, and SinoMed) were searched. …”
    Get full text
    Article
  3. 2143

    Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life by Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron

    Published 2022-07-01
    “…Outcomes measuring skin clearance, itch, and quality of life were evaluated.Results Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo.Conclusion Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life.ClinicalTrials.gov NCT02780167, NCT03349060, NCT03575871…”
    Get full text
    Article
  4. 2144
  5. 2145
  6. 2146

    Weight gain secondary to the use of oral Janus kinase inhibitors: A systematic review and meta-analysis by Grace Xiong, BHSc, Eric Yu, Martin Heung, Jaehyeong Yang, BSc, Megan Lowe, MPH, Mohannad Abu-Hilal, MD

    Published 2025-04-01
    “…Ovid MEDLINE, Embase, Web of Science, and Clinicaltrials.gov were searched up to April 2024. From 1080 initial articles, 90 studies covering 16,000 patients were selected. …”
    Get full text
    Article
  7. 2147
  8. 2148
  9. 2149

    The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials. by Qiufeng Zhou, Guozheng Zhao, Yu Pan, Ying Zhang, Yuehua Ni

    Published 2024-01-01
    “…<h4>Methods</h4>MEDLINE, EMBASE, Cochrane Library and clinicaltrials.gov were searched for RCTs which were performed to evaluate fluvoxamine and placebo up to January 31, 2024. …”
    Get full text
    Article
  10. 2150

    Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure by David Carballo, Jérôme Stirnemann, Nicolas Garin, Chistophe Marti, Jacques Serratrice, Sebastian Carballo

    Published 2020-06-01
    “…Methods and results Between November 2014 and May 2019, 799 patients were recruited in a prospective registry of acute heart failure at the University Hospitals of Geneva (ClinicalTrials.gov: NCT02444416). The cohort consists of consecutive patients admitted to the Department of Medicine with ADHF. …”
    Get full text
    Article
  11. 2151
  12. 2152

    A randomized, double‐blind, placebo‐controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease by Darren Bentley, Marie Mannino, Marianne Manchester, Priscila Camillo Teixeira, Bernhard Reis, Malcolm Boyce, Sandra Nagel

    Published 2025-01-01
    “…This randomized, double‐blind, placebo‐controlled, parallel‐group, single‐center study tested the effects of the cathepsin S inhibitor RO5459072 on the immune response to a 13‐day gluten challenge in 19 participants with celiac disease (ClinicalTrials.gov: NCT02679014). Nine participants in the RO5459072 arm received 100 mg study drug b.i.d. (200 mg daily); 10 received a placebo. …”
    Get full text
    Article
  13. 2153
  14. 2154

    Permeability of the blood-brain barrier through the phases of ischaemic stroke and relation with clinical outcome: protocol for a systematic review by Helena Donato, Sara Bernardo-Castro, Lino Ferreira, João Sargento-Freitas

    Published 2020-09-01
    “…In addition, grey literature and ClinicalTrials.gov will be scanned. We will include randomised controlled trials, cohort, cross-sectional and case-controlled studies on humans that quantitatively assess the BBBP in stroke. …”
    Get full text
    Article
  15. 2155

    Effectiveness of home-based exercise for functional rehabilitation in older adults after hip fracture surgery: A systematic review and meta-analysis of randomized controlled trials... by Lijun Zhao, Xiaona Zhao, Bin Dong, Xiaobin Li

    Published 2024-01-01
    “…Comprehensive literature search was performed on PubMed, EMBASE, Web of Science, Cochrane library, and Clinicaltrails.gov to identify eligible randomized controlled trials (RCTs). …”
    Get full text
    Article
  16. 2156
  17. 2157

    Iron:The missing link of depression prevention and treatment by reza pakzad, Mohammadamin Jandaghian Bidgoli, fatemeh abdi, negin shaterian

    Published 2024-09-01
    “…Methods: International databases like Web of Science, PubMed, Cochrane,  International Clinical Trials Registry Platform, Clinicaltrials.gov, and Scopus were searched until 27 July 2024 to identify eligible articles with the appropriate Medical Subject Headings (MeSH).  …”
    Get full text
    Article
  18. 2158
  19. 2159

    Functional MRI-guided microsurgery of intracranial arteriovenous malformations: study protocol for a randomised controlled trial by Shuo Wang, Yuanli Zhao, Jun Wu, Bing Zhao, Yong Cao

    Published 2014-10-01
    “…Study findings will be disseminated in the printed media.Trial registration number ClinicalTrials.gov NCT01758211.…”
    Get full text
    Article
  20. 2160